

Proceeding Paper

# Multi-Drug Resistance in Extended Spectrum Beta Lactamase (Esb1) Producing *Escherichia coli* Isolates from Selected Cattle Farms in Ibadan, Oyo State †

Esther Enioto Adesanwo \*, Victoria Olusola Adetunji, Samuel Ajulo, Oluwatobi Fasiku, Oluwadamilola Oni, Oluayemi Okunlade and Adebayo Awoyele

Faculty of Veterinary Medicine, University of Ibadan, 200132 Ibadan, Nigeria; email1@email.com (V.O.A.); email2@email.com (S.A.); email3@email.com (O.F.); email4@email.com (O.O.); email1@email.com (O.O.); email2@email.com (A.A.)

\* Correspondence: eniotoadesanwo@gmail.com

† Presented at the 3rd International Electronic Conference on Antibiotics (ECA 2023), 1–15 December 2023, Available online: <https://eca2023.sciforum.net/>.

**Abstract:** Antimicrobial resistance (AMR) has been recorded as a fast-growing One Health challenge globally. The major driver of AMR is the inappropriate use of antibiotics in humans and animals. A substantial volume of antimicrobials is consumed by the animal industry for treatment of *Escherichia coli* (*E. coli*) infections which is a challenge, therefore the understanding of AMR in animals is critical in solving this rising One Health problem. This study assessed the resistance level of some critically important antibiotics to *E. coli* bacteria isolates from cattle faecal samples. A total of twenty-eight composite (n = 5) faecal samples were collected from farms in four different Local Governments Areas (LGAs) within Ibadan; Akinyele LGA:7, Ibadan north LGA:12, Ido LGA:4 and Lagelu LGA:5. Standard microbiological methods were used for isolation, Antibiotics Sensitivity Test (AST) and ESBL production. A total of 22 (78.6%) *E. coli* isolates were recovered, and the results showed resistance to critically important antibiotics in ascending order; Streptomycin (0.00%), Meropenem (0.00%), Gentamicin (4.55%), Ceftazidime (18.8%), Sulphamethazole (22.73%), Cefotaxime (54.55%), Ampicillin (63.64%), Pefloxacin (81.82%), Amoxicillin-Clavulanate (100%). Of the 22 positive *E. coli* isolates, 8 (36.4%) were ESBL-producing and 17 (60.7%) were multi-drug resistant. The ESBL enzymes share the ability to hydrolyze third-generation Cephalosporin and this makes ESBL-producing *E. coli* exhibit resistance to antibiotics (especially the Cephalosporins). The result shows the possibility of AMR becoming a looming pandemic, globally. The presence of multi-drug resistant ESBL *E. coli* in cattle in Ibadan was established. The resistance to third-generation Cephalosporin antibiotics is of public health significance. Ensuring Antimicrobial stewardship and prescription-based medication, alternatives therapies to antibiotics and adoption of a collaborative approach are measures to preventing AMR pandemic.

**Keywords:** *E. coli*; ESBL; cattle faecal sample; antimicrobial resistance

**Citation:** Adesanwo, E.E.; Adetunji, V.O.; Ajulo, S.; Fasiku, O.; Oni, O.; Okunlade, O.; Awoyele, A.

Multi-Drug Resistance in Extended Spectrum Beta Lactamase (Esb1) Producing *Escherichia Coli* Isolates from Selected Cattle Farms in Ibadan, Oyo State. *Med. Sci. Forum* 2023, 24, x.

<https://doi.org/10.3390/xxxxx>

Academic Editor(s): Name

Published: 1 December 2023



**Copyright:** © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The worldwide need for animal protein is growing, which has resulted in the global spread of intensive farming (Christie et al., 2018, Ranyal et al., 2023) This global expansion has indirectly led to an increase in the usage of antimicrobials by farmers as growth boosters and treatment of animal illnesses (Thomas et al., 2015, Hosain et al., 2021). Antibiotic resistance has occurred from increased use and inadequate antimicrobial stewardship, which has resulted in inefficient treatment of certain bacterium illnesses (CDC, 2022, Banan, et al., 2023).



We collected the samples within the first two weeks and laboratory analysis was done during the period of January to April 2022. The total duration of the study lasted from November 2021 to June 2022. The study population consists of fresh fecal samples of Cattle from the farms.

## 2.2. Sample Size Estimation

The minimum sample size was calculated using this formula by Thrusfield (2005): Sample size,  $n = z^2 p(1 - p)/d^2$  where,  $n$  = minimum sample size calculated  $z$  = Score for a given confidence interval at 95% is 1  $p$  = Known or estimated of prevalence rate  $d$  = level of precision (5%)

Therefore, for *Escherichia coli* it has a prevalence rate of 89.5% (Eyitayo et al., 2015)

$$n = 1.962 \times 0.085(1 - 0.0895) / 0.052$$

$$n = 3.8416 \times 0.0895 \times 0.105 / 0.0025$$

$$n = 0.361 / 0.0025 \quad n = 144.4 \text{ approx. } 144$$

The sample size is 144 fecal materials. 28 composite fecal samples were collected, with each composite sample comprising of 5 fecal materials ( $n = 28 \times 5$ ). This gives a total of  $n = 140$  fecal samples.

The sample size is 144 fecal materials. 28 composite fecal samples were collected, with each composite sample comprising of 5 fecal materials ( $n = 28 \times 5$ ). This gives a total of  $n = 140$  fecal samples.

## 2.3. Microbiological Analysis

Fresh fecal samples were collected aseptically in composite of 5 and a total of 28 composite samples were collected ( $n = 140$ ). Samples were incubated overnight in 1% buffered peptone water. Aliquots of overnight culture was the inoculated unto MacConkey agar without cefaxamine and MacConkey agar with cefaxamine to identify commensal *E. coli* and presumptive ESBL producing *E. coli*. Two isolates from each plate were selected for biochemical for confirmation of *E. coli*. The selected isolates were purified to obtain discrete colonies. Pure isolates were inoculated on Eosin Methylene Blue (EMB) and Chromogenic (ECC) agars. *E. coli* gives a Green metallic sheen color on EMB agar plates and blue colonies ECC. Isolates that were catalase positive, indole positive and oxidase negative were confirmed to be *E. coli*.

## 2.4. Antibiotics Susceptibility Tests (AST)

Antibiotics susceptibility tests were carried out using the disc diffusion method described by Kirby Bauer et al (1996). The antibiotics discs used include: Chloramphenicol (C30), Pefloxacin (PEF5), Gentamicin (CN10), Sulphamethazole (SXT25), Tetracycline (TE30), Ampicillin (AMP10), Cefotaxime (CTX30), Ceftazidime (CAZ30), Streptomycin (S300), Amoxicillin + Clavulinic acid (AMC30), Meropenem (MEM10). The zone of inhibition were measured and interpreted based on Clinical and Laboratory Standards Institute (CLSI) (2021).

## 2.5. Detection of Esbl Producing *E. coli* Using Double Disk Synergy Test

All the Cefotaxime and Ceftazidime resistant *E. coli* isolates were selected as presumptive ESBL *E. coli* isolates, for confirmatory ESBL detection using the double disk synergy test previously described by Lu et al (2010). The test was carried out using ESBL-kit, a combination of Cefotaxime (CTX 30) and Clavulinic acid (CTL) placed at a distance of 15–20mm from each other (center to center). The plates were observed after incubating at 37 °C for 18–24 h.

ESBL producing *E. coli* isolates were confirmed by subtracting the CTX diameter from the CTL diameter (CTX – CTL). The zone of diameter that is >15 mm confirms ESBL producing *E. coli* isolates.

#### 2.6. Data Analysis

Data was analyzed by using descriptive statistics, proportions and percentages, and presented in form of tables and figures. The level of significance was set at  $p \leq 0.05$ . The ANOVA (Analysis of Variance) values were used to ascertain significance in antibiotic sensitivity testing.

#### 2.7. Ethical Considerations

Consent of owners of these farms were sought before taking samples from their cattle. All contaminated materials and media were decontaminated by autoclaving and or incineration.

### 3. Results

#### 3.1. Occurrence of *Escherichia coli*

Occurrence of *E. coli* was 22/28 (78.6%). All isolates showed multi-drug resistance and 7 (25.01%) were confirmed to be positive ESBL producing isolates.

#### 3.2. Antibiotic Susceptibility of *E. coli* in Cattle

A zone of clearance which signifies bacteria susceptibility and lack of clearance which signifies bacteria resistant were observed.

**Table 1.** Antibigram profile *Escherichia coli* isolates (%) from Cattle within Ibadan, Nigeria.

Subclass	Antibiotics	Percent	Percentage	Percentage
		Age Susceptible (n= 22)	Intermediate (n = 22)	Resistant (n = 22)
Aminoglycosides	Gentamicin CN10	81.82	13.64	4.55
	Streptomycin S300	95.45	4.55	0.00
Cephalosporin III	Cefotaxime CTX30	13.64	31.82	54.55
	Ceftazidime CAZ30	54.55	27.27	18.18
Quinolones	Pefloxacin PEF5	18.18	0.00	81.82
Aminopenicillin	Ampicillin AMP10	18.18	18.18	63.64
Folate Path Inhibitor	way Sulphamethazole/Tri methopr im SXT25	22.73	54.55	22.73
Phenicols	Chloramphenicol C30	68.18	18.18	13.64
Tetracyclines	Tetracycline TE30	27.27	18.18	54.55
Carbapenems	Meropenem MEM10	90.91	9.09	0.00
B-lactam lactamase	+B- Amoxicillin + Clavanalic Acid	0.00	0.00	100.00

**Table 2.** Antimicrobial-resistant pattern of *Escherichia coli* isolates (%) from cattle in different location in Ibadan, Nigeria.

Subclass	Antibiotics	Akinyel	Ibadan	Ido	Lagel u
		e (n = 19)	North (n = 44)	(n = 4)	(n = 2)
Aminoglycosides	Gentamicin CN10	0.0	72.7	0.0	0.0
	Streptomycin S300	0.00	0.00	0.00	0.00
Cephalosporin III	Cefotaxime CTX30	80.0	36.4	75.0	50.0
	Ceftazidime CAZ30	0.0	18.2	25.0	50.0
Quinolones	Pefloxacin PEF5	80.0	72.7	100.0	100.0
Penicillin	Ampicilin AMP10	60.0	36.4	75.0	100.0
Folate Pathway Inhibitor	Sulphamethazole/Trimetho prim SXT25	20.0	9.1	25.0	50.0
Amphenicols	Chloramphenicol C30	0.0	9.1	50.0	0.0
Tetracyclines	Tetracycline TE30	80.0	18.2	75.0	50.0
Carbapenems	Meropenem MEM10	0.0	0.0	0.0	0.0

3.3. Prevalence of Esbl Producing *E. coli* Isolates

Of the 12 (54.5%) presumptive ESBL producing *E. coli* isolates, 7 (25.01%) were recorded confirmatory as ESBL producing isolates using the double disk synergy test.

3.4. Antibigram of Esbl and Non-Esbl Producing *E. coli*

The Figures 1 and 2 gives a graphical chart on the antibiotics susceptibility pattern of the Confirmed ESBL *E. coli* isolates and the Non-ESBL producing isolates.

From the Figure 1 below, the ESBL producing isolates shows higher antibiotic resistance compared to the non-ESBL isolates in Figure 2. This is an expected outcome, as the ESBL isolates are the resistant genes that renders antibiotics ineffective against the bacteria.




Figure 1. A chart showing the Antibiogram of ESBL producing *E. coli* isolates.




Figure 2. A chart showing the Antibiogram of Non-ESBL producing *E. coli* isolates.

#### 4. Discussion

##### 4.1. ESBL-Producing *E. coli*

In this study, Of the 12 (54.5%) presumptive ESBL producing *E. coli* isolates, 7(25.01%) were recorded confirmatory as ESBL producing isolates. *E. coli* isolates showed multidrug resistance to the antibiotics used at various degrees, with the ESBL producing isolates having resistance to more antibiotics than the non-ESBL producing isolates. This result agrees with the findings of other researchers who reported multidrug resistance among *E. coli* isolates (Schroeder et al., 2002 and Ojo et al., 2009).

A study carried out on the dam and calves in Germany revealed that the mean farm ESBL/AmpC-*E. coli* prevalence in calves was almost 3.5 times higher (mean = 63.5%) than that of the dams (mean = 18.0%). Nearly 14% of the calf-cow pairs were positive for ESBL/AmpC-*E. coli* (Weber et al., 2021). The high prevalence in the calves could be due to their low immunity development which could predispose them to infections.

#### 4.2. Antibigram of ESBL and Non-ESBL *E. coli* Isolates

The comparison of the Antibigram of ESBL and Non-ESBL producing *E. coli* isolates shows a significant resistance pattern. From Figure 1, the ESBL producing isolates shows low susceptibility and high resistance to the antibiotics, while the reverse was the case with the Non-ESBL producing isolates (Figure 2). The high resistant displayed by the ESBL producing isolate was expected as the ESBL genes are produced by *E. coli* bacteria to protect them from destruction by the antibiotics.

The indiscriminate use of antibiotics is the main cause of emergence, selection and discrimination of drug-resistant genes in bacteria important in both veterinary and human medicine (Smith et al., 2005). In Nigeria, veterinary drugs are sold and used without much control. This indiscriminate usage and non-adherence to withdrawal periods is responsible for the spread of resistant genes like the ESBLs within the bacteria population in food animals and humans by extension. These resistant bacteria are rendering the second- and third-line antibiotics ineffective and this may return us to the pre-antibiotic era (WHO, 2000).

#### 4.3. Conclusions

In Nigeria, large number of antimicrobials goes into use without Veterinarians' prescriptions particularly as antibiotics are available over-the-counter (OTC) (Ojo et al., 2014). Farmers or cattle handlers result to self-medication due to lack of adequate and high cost of veterinary services as a result increasing the chances of antimicrobial resistance.

### 5. Recommendation

To reduce and/or eliminate the pathogens in Cattle, the following are therefore recommended:

1. The high multidrug resistant isolates are of public health importance. The need for a one health approach involving collaborations with microbiologists, veterinarians, cattle breeders, public health Practitioners and other One health related professionals in Nigeria for containment of AMR is highly recommended.
2. Alternative medication can be used in place of antibiotics, such as; Probiotics, Bacteriophages and Therapy.
3. Biosecurity measures should be strictly adhered to and management of farm animals and their environment should be of utmost priority.
4. Proper Antimicrobial stewardship by Veterinary professionals should be ensured before any drug is recommended and administered.
5. Farmers should employ good hygiene n management of their Cattle farms.
6. There should be increased awareness among farmers on the likelihood of Cattle as a potential source of foodborne diseases and how to prevent it. Government and extension agents could work to achieve this.
7. Withdrawal period after drug administration is important to prevent antibiotics resistance in humans, which can be fatal on occurrence. The farmers should ensure not to sell Cattle that has just been administered antimicrobial drugs, until the withdrawal period elapses.
8. Carriers or clinically sick animals should be isolated and treated separately by the veterinary professionals.
9. A ban in the usage of antimicrobial drugs which are no longer effective in treatment of these pathogens. This will help prevent the bacteria organisms from building more resistant genes.
10. Further research work to involve the use of molecular characterization to determine resistant genes, and whole-genome sequencing. This will ensure the researchers are at the cutting edge and are constantly ready to curb any form of diseases outbreak.

### References

1. Adeyemi, K.; Okunroumu, P.; Olagbende, A.; Adedokun, O.; Hassa, A.W.; Atilola, G. High prevalence of multi-drug resistant enteric bacteria. *Evid. A Teach. Hosp. South. West. Niger. J.* **2020**, *13*, 651–656.
2. Aiesh, B.M.; Nazzal, M.A.; Abdelhaq, A.I.; Abutaha, S.A.; Zyoud, S.H.; Sabateen, A. Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics. *Sci. Rep.* **2023**, *13*, 1–9. Available online: [www.nature.com/scientificreports](http://www.nature.com/scientificreports) (accessed on).
3. Ben-Ami, R.; Rodríguez-Baño, J.; Arslan, H.; Pitout, J.D.; Quentin, C.; Calbo, E.S.; Azap, O.K.; Arpin, C.; Pascual, A.; Livermore, D.M.; et al. A multinational survey of risk factors for infection with extended-spectrum  $\beta$ -lactamase-producing enterobacteriaceae in nonhospitalized patients. *Clin. Infect. Dis.* **2009**, *49*, 682.
4. Bradford, P.A. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* **2001**, *14*, 933.
5. Danladi, W.D. Multidrug resistance to commonly prescribed antibiotics in *E. coli* isolated from Barbecued beef sold in Nigerian City. *Pan Afr. Med. J.* **2021**, *39*.
6. Ekiomado, R.; Adewumi, F.; Bamidele, T. Antibiotic resistance and plasmid analysis of Enterobacteriaceae isolated from retail meat in Lagos, Nigeria. *One Health Outlook* **2021**, *3*, 1–6.
7. Evans, J.; Hannodee, M.; Wittler, M. Amoxicillin-Clavulanate. *Exp. Biol. Med. J.* **2021**, *73*, 523–528.
8. Hosain, M.Z.; Kabir, S.M.L.; Kamal, M.M. Antimicrobial uses for livestock production in developing countries. *Vet. World J.* **2021**, *14*, 210–221. Available online: [www.doi.org/10.14202/vetworld.2021.210-221](http://www.doi.org/10.14202/vetworld.2021.210-221) (accessed on).
9. Masse, J.; Hekene, L.; Fairbrother, J.; Jean-Philippe, R.; Francoz, D.; Dufour, S.; Archambault, M. Prevalence of Antimicrobial Resistance and Characteristics of Escherichia coli isolates from Feecal and Manure Pit Samples on Dairy Farms in Province of Quebec, Canada. *Front. Vet. Sci.* **2021**, *8*, 438.
10. NandaKafle, G.; Christie, A.A.; Vilain, S.; Brözel, V.S. Growth and extended survival of Escherichia coli O157: H7 in soil organic matter. *Front. Microbiol.* **2018**, *9*, 762.
11. Ojo, O.E.; Fabusoro, E.; Majasan, A.A.; Dipeolu, M.A. Antimicrobials in animal production: Usage and practices among livestock farmers in Oyo and Kaduna States of Nigeria. *Trop. Anim. Health Prod.* **2016**, *48*, 189–197.
12. Smith, D.L.; Levin, S.A.; Laxminarayan, R. Strategic interactions in multiinstitutional epidemics of antibiotic resistance. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3153–3158.
13. Thomas, P.; Boeckela, V.; Brower, C.; Gilbert, M.; Bryan, T.; Simon, A.; Timothy, P.; Teillant, A.; Laxminarayan, R. Global trends in antimicrobial use in food animals. *Pub. Med.* **2015**, *10*, 1073.
14. Weber, L.P.; Dreyer, S.; Heppelmann, M.; Schaufler, K.; Homeier-Bachmann, T.; Bachmann, L. Prevalence and risk factors for ESBL/AmpC-*E. coli* in pre-weaned dairy calves on dairy farms in Germany. *Microorganisms* **2021**, *9*, 2135.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.